Abstract
Background and Objective: With the popularization of guideline-based secondary prevention based on traditional risk factors, rates of stroke recurrence reduced greatly after ischemic stroke (IS) or transient ischemic attack (TIA), but the residual risk still exists. We aim to evaluate which IS subtype benefits the most from the current secondary prevention and to evaluate nontraditional risk factors for residual recurrence risk of different IS etiologies. Methods: The study included IS/TIA patients who participated in both biomarker substudy and imaging substudy of the Third China National Stroke Registry. We used 5 guideline-recommended interventions (antiplatelet, statins, anticoagulant, antihypertensive, and antidiabetic therapies) to document the performance of secondary prevention care. Residual risk was defined as the risk of stroke recurrence despite adherence to these 5 guideline-based secondary prevention strategies. Risk factors associated with stroke recurrence were analyzed by using Cox regression models. Results: In total, 9,733 patients were included in this study. At 3 months, 4,186 (43.0%) patients adhered to 5 secondary prevention strategies, and the residual risk of recurrence was 5.1%. According to Trial of Org 10172 in Acute Stroke Treatment subtypes, cardioembolism benefited the most from current secondary prevention (relative risk reduction: 65.2%), followed by large-artery atherosclerosis (LAA) (29.0%) and small-artery occlusion (SAO) (20.0%). Despite adhering to secondary prevention strategies, high sensitivity C-reactive protein, interleukin-6 (IL-6) levels, and impaired renal function were independent risk factors for the residual recurrence risk of LAA subtype, while IL-6 and trimethylamine N-oxide significantly contributed to the residual risk of SAO subtype. Conclusions: LAA and SAO subtypes own the specific nontraditional risk factors while inflammation is a common risk factor for residual recurrence risk of both.
References
1.
Hong
KS
, Yegiaian
S
, Lee
M
, Lee
J
, Saver
JL
. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design
. Circulation
. 2011
;123
(19
):2111
–9
. .2.
Amarenco
P
, Lavallée
P
, Labreuche
J
, Albers
G
, Bornstein
N
, Canhão
P
, One-year risk of stroke after transient ischemic attack or minor stroke
. N Engl J Med
. 2016
;374
(16
):1533
–42
.3.
Ridker
P
, Everett
B
, Thuren
T
, MacFadyen
J
, Chang
W
, Ballantyne
C
, Antiinflammatory therapy with canakinumab for atherosclerotic disease
. N Engl J Med
. 2017
;377
(12
):1119
–31
.4.
Curry
S
, Krist
A
, Owens
D
, Barry
M
, Caughey
A
, Davidson
K
, Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement
. JAMA
. 2018
;320
(3
):272
–80
.5.
Wang
Y
, Jing
J
, Meng
X
, Pan
Y
, Wang
Y
, Zhao
X
, The third China national stroke registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics
. Stroke Vasc Neurol
. 2019
;4
(3
):158
–64
.6.
Stroke: 1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders
. Stroke
. 1989
;20
(10
):1407
–31
. .7.
Li
X
, Obeid
S
, Wang
Z
, Hazen
B
, Li
L
, Wu
Y
, Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes
. Eur Heart J
. 2019
;40
(32
):2700
–9
.8.
Mora
S
, Rifai
N
, Buring
JE
, Ridker
PM
. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events
. Circulation
. 2006
;114
(5
):381
–7
. .9.
Teo
B
, Xu
H
, Wang
D
, Li
J
, Sinha
A
, Shuter
B
, GFR estimating equations in a multiethnic Asian population
. Am J Kidney Dis
. 2011
;58
(1
):56
–63
.10.
Adams
H
, Bendixen
B
, Kappelle
L
, Biller
J
, Love
B
, Gordon
D
, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment
. Stroke
. 1993
;24
(1
):35
–41
.11.
Park
H
, Kim
B
, Han
M
, Park
J
, Kang
K
, Lee
S
, One-year outcomes ater minor stroke or high-risk transient ischemic attack: Korean multicenter stroke registry analysis
. Stroke
. 2017
;48
(11
):2991
–8
.12.
European Stroke Organisation (ESO) Executive Committee
; ESO Writing Committee
. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008
. Cerebrovasc Dis
. 2008
;25
(5
):457
–507
. .13.
Cao
J
, Arnold
A
, Manolio
T
, Polak
J
, Psaty
B
, Hirsch
C
, Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study
. Circulation
. 2007
;116
(1
):32
–8
.14.
Zakai
N
, Katz
R
, Jenny
N
, Psaty
B
, Reiner
A
, Schwartz
S
, Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study
. J Thromb Haemost
. 2007
;5
(6
):1128
–35
.15.
Anavekar
N
, McMurray
J
, Velazquez
E
, Solomon
S
, Kober
L
, Rouleau
J
, Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
. N Engl J Med
. 2004
;351
(13
):1285
–95
.16.
Go
A
, Fang
M
, Udaltsova
N
, Chang
Y
, Pomernacki
N
, Borowsky
L
, Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study
. Circulation
. 2009
;119
(10
):1363
–9
.17.
Liu
H
, Qian
S
, Zhong
C
, Wang
A
, Peng
Y
, Peng
H
, Predictive value of cystatin C for stroke recurrence in patients with acute ischemic stroke
. Circ J
. 2021
;85
(2
):213
–9
.18.
Toole
JF
, Malinow
MR
, Chambless
LE
, Spence
JD
, Pettigrew
LC
, Howard
VJ
, Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial
. JAMA
. 2004
;291
(5
):565
–75
.19.
Xu
J
, Cheng
A
, Song
B
, Zhao
M
, Xue
J
, Wang
A
, Trimethylamine N-oxide and stroke recurrence depends on ischemic stroke subtypes
. Stroke
. 2021
:Strokeaha120031443
. Epub ahead of print.20.
Hansson
GK
, Libby
P
. The immune response in atherosclerosis: a double-edged sword
. Nat Rev Immunol
. 2006
;6
(7
):508
–19
. .21.
Weber
C
, von Hundelshausen
P
. CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting
. Circ Res
. 2017
;121
(10
):1119
–21
. .22.
Ridker
P
, Libby
P
, MacFadyen
J
, Thuren
T
, Ballantyne
C
, Fonseca
F
, Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
. Eur Heart J
. 2018
;39
(38
):3499
–507
.23.
Ridker
PM
, MacFadyen
JG
, Everett
BM
, Libby
P
, Thuren
T
, Glynn
RJ
. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
. Lancet
. 2018
;391
(10118
):319
–28
. .24.
Shine
B
, de Beer
FC
, Pepys
MB
. Solid phase radioimmunoassays for human C-reactive protein
. Clin Chim Acta
. 1981
;117
(1
):13
–23
. .25.
Mitaki
S
, Nagai
A
, Oguro
H
, Yamaguchi
S
. C-reactive protein levels are associated with cerebral small vessel-related lesions
. Acta Neurol Scand
. 2016
;133
(1
):68
–74
. .26.
Low
A
, Mak
E
, Rowe
JB
, Markus
HS
, O’Brien
JT
. Inflammation and cerebral small vessel disease: a systematic review
. Ageing Res Rev
. 2019
;53
:100916
. .27.
Wang
Z
, Klipfell
E
, Bennett
B
, Koeth
R
, Levison
B
, Dugar
B
, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
. Nature
. 2011
;472
(7341
):57
–63
.28.
Haghikia
A
, Li
X
, Liman
T
, Bledau
N
, Schmidt
D
, Zimmermann
F
, Gut microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes
. Arterioscler Thromb Vasc Biol
. 2018
;38
(9
):2225
–35
.29.
Zhu
W
, Gregory
J
, Org
E
, Buffa
J
, Gupta
N
, Wang
Z
, Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk
. Cell
. 2016
;165
(1
):111
–24
.30.
Zhuang
R
, Ge
X
, Han
L
, Yu
P
, Gong
X
, Meng
Q
, Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis
. Obes Rev
. 2019
;20
(6
):883
–94
.31.
Ge
X
, Zheng
L
, Zhuang
R
, Yu
P
, Xu
Z
, Liu
G
, The gut microbial metabolite trimethylamine N-oxide and hypertension risk: a systematic review and dose-response meta-analysis
. Adv Nutr
. 2020
;11
(1
):66
–76
.32.
Putaala
J
, Haapaniemi
E
, Gordin
D
, Liebkind
R
, Groop
P
, Kaste
M
, Factors associated with impaired kidney function and its impact on long-term outcome in young ischemic stroke
. Stroke
. 2011
;42
(9
):2459
–64
.33.
Kokubo
Y
. Carotid atherosclerosis in kidney disease
. Contrib Nephrol
. 2013
;179
:35
–41
. .34.
Hao
Z
, Wu
B
, Lin
S
, Kong
F
, Tao
W
, Wang
D
, Association between renal function and clinical outcome in patients with acute stroke
. Eur Neurol
. 2010
;63
(4
):237
–42
.35.
Rogers
M
, Goettsch
C
, Aikawa
E
. Medial and intimal calcification in chronic kidney disease: stressing the contributions
. J Am Heart Assoc
. 2013
;2
(5
):e000481
. .36.
Recio-Mayoral
A
, Banerjee
D
, Streather
C
, Kaski
JC
. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease: a cross-sectional study of predialysis, dialysis and kidney-transplantation patients
. Atherosclerosis
. 2011
;216
(2
):446
–51
. .37.
Moody
W
, Edwards
N
, Madhani
M
, Chue
C
, Steeds
R
, Ferro
C
, Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?
Atherosclerosis
. 2012
;223
(1
):86
–94
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
